Antibodies binding C5 and uses thereof
AssigneeBiosion Inc.
InventorsMingjiu Chen, Shukai Xia
Life of this patent
Estimating the term…
Abstract
An isolated monoclonal antibody that specifically binds human C5, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. Further provided are a bispecific molecule, an immunoconjugate, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or the antigen-binding portion thereof, as well as a treatment method using an anti-C5 antibody or the antigen-binding portion thereof.
Claims15
An isolated monoclonal antibody, or an antigen-binding portion thereof, capable of binding to complement component 5, comprising
- (i) a heavy chain variable region that comprises a VH CDR1 region, a VH CDR2 region and a VH CDR3 region;
- and
- (ii) a light chain variable region that comprises a VL CDR1 region, a VL CDR2 region and a VL CDR3 region,
- wherein the VH CDR1 region, the VH CDR2 region, the VH CDR3 region, the VL CDR1 region, the VL CDR2 region and the VL CDR3 region comprise amino acid sequences set forth in (1) SEQ ID NOs:
- 1, 7, 14, 20, 25 and 31, respectively;
- (2) SEQ ID NOs:
- 2, 8, 15, 20, 26 and 32, respectively;
- (3) SEQ ID NOs:
- 2, 8, 16, 20, 25 and 33, respectively;
- (4) SEQ ID NOs:
- 3, 9, 17, 21, 27 and 34, respectively;
- (5) SEQ ID NOs:
- 4, 10, 18, 22, 28 and 35, respectively;
- (6) SEQ ID NOs:
- 4, 11, 18, 22, 28 and 35, respectively;
- (7) SEQ ID NOs:
- 4, 12, 18, 23, 29 and 36, respectively;
- (8) SEQ ID NOs:
- 5, 12, 18, 23, 29 and 36, respectively;
- or (9) SEQ ID NOs:
- 6, 13, 19, 24, 30 and 37, respectively.
An antibody, or an antigen-binding portion thereof, capable of binding to complement component 5, comprising a heavy chain variable region and a light chain variable region,
- wherein the heavy chain variable region and the light chain variable region comprise amino acid sequences having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to
- (1) SEQ ID NOs:
- 38 and 44, respectively, wherein 18th, 92nd and 106th amino acid residues in SEQ ID NO:
- 44 are S, S and F, respectively;
- (2) SEQ ID NOs:
- 39 and 59, respectively, wherein 29th, 71st, 102nd and 107th amino acid residues in SEQ ID NO:
- 39 are I, I, S and F, respectively;
- (3) SEQ ID NOs:
- 39 and 44, respectively, wherein 29th, 71st, 102nd and 107th amino acid residues in SEQ ID NO:
- 39 are L, M, G and L, respectively, wherein 18th, 92nd and 106th amino acid residues in SEQ ID NO:
- 44 are T, H and I, respectively;
- (4) SEQ ID NOs:
- 40 and 45, respectively;
- (5) SEQ ID NOs:
- 41 and 46, respectively, wherein 58th and 60th amino acid residues in SEQ ID NO:
- 41 are T and N respectively;
- (6) SEQ ID NOs:
- 41 and 46, respectively, wherein 58th and 60th amino acid residues in SEQ ID NO:
- 41 are S and F, respectively;
- (7) SEQ ID NOs:
- 42 and 47, respectively, wherein 74th amino acid residue in SEQ ID NO:
- 42 is R;
- (8) SEQ ID NOs:
- 42 and 47, respectively, wherein 74th amino acid residue in SEQ ID NO:
- 42 is K;
- or
- (9) SEQ ID NOs:
- 43 and 48, respectively.
Dependencies are inferred from the claim text.